Eli Lilly Sec Filings

Publicly traded companies in the United States are required by the Securities and Exchange Commission (SEC) to disclose certain financial and operational information regularly. Eli Lilly and Company, a global pharmaceutical leader, complies with these regulations through various SEC filings. These documents provide investors, analysts, and the public with insights into the company’s financial health, business strategies, executive compensation, and more. Understanding these filings is crucial for anyone looking to assess Eli Lilly’s performance and prospects.

Overview of SEC Filings

The SEC mandates that companies submit specific forms at regular intervals. These filings are publicly accessible and serve as a transparent record of a company’s activities. For Eli Lilly, key filings include

• Form 10-KAn annual report detailing the company’s financial performance, risks, and business activities.
• Form 10-QQuarterly reports that provide updates on financial performance and operations.
• Form 8-KCurrent reports that disclose significant events or corporate changes.
• Proxy StatementsDocuments that inform shareholders about matters to be discussed at annual meetings, including executive compensation and board elections.
• Form 4Statements of changes in beneficial ownership of securities, often used to report insider trading activities.

These filings are accessible through the SEC’s EDGAR database and Eli Lilly’s investor relations website. They offer a comprehensive view of the company’s financial health and strategic direction.

Recent SEC Filings by Eli Lilly

As of September 2025, Eli Lilly has submitted several significant filings

• Form 10-Q (May 1, 2025)This quarterly report provides insights into the company’s financial performance for the first quarter of 2025. It includes income statements, balance sheets, and cash flow statements, along with management’s discussion and analysis of financial conditions.
• Form 10-K (February 19, 2025)The annual report for the fiscal year ending December 31, 2024, offers a detailed overview of the company’s financial results, risk factors, and strategic initiatives. It also includes audited financial statements and disclosures about executive compensation and corporate governance practices.
• Form 8-K (August 7, 2025)A current report disclosing significant events, such as changes in executive leadership or major business developments.
• Form 4 Filings (Various Dates)Statements reporting insider transactions, including purchases and sales of Eli Lilly stock by executives and directors. These filings are closely monitored by investors as they can indicate insider confidence in the company’s future performance.

These documents are available on Eli Lilly’s SEC Filings page and provide valuable information for stakeholders.

Importance of SEC Filings

SEC filings are essential tools for investors and analysts. They offer

• TransparencyDetailed financial statements and disclosures help stakeholders understand the company’s performance and risks.
• AccountabilityRegular filings ensure that the company adheres to legal and regulatory standards.
• Decision-Making SupportInvestors use these documents to make informed decisions about buying, holding, or selling stock.
• Corporate Governance InsightsProxy statements provide information on board structures, executive compensation, and shareholder proposals.

By reviewing these filings, stakeholders can gain a clearer picture of Eli Lilly’s operations and strategic direction.

Accessing Eli Lilly’s SEC Filings

To access Eli Lilly’s SEC filings, visit their investor relations website. Here, you can find

• Comprehensive FilingsAll submitted SEC forms, including 10-Ks, 10-Qs, 8-Ks, and proxy statements.
• Financial ReportsAnnual and quarterly reports with detailed financial data.
• Press ReleasesOfficial announcements regarding business developments and financial results.
• Investor PresentationsMaterials from investor meetings and conferences.

These resources are invaluable for anyone seeking to analyze Eli Lilly’s financial health and business strategies.

Eli Lilly’s SEC filings are vital resources for understanding the company’s financial performance, strategic initiatives, and corporate governance. By regularly reviewing these documents, investors and analysts can make informed decisions and stay updated on the company’s developments. Accessing these filings is straightforward through Eli Lilly’s investor relations website, ensuring transparency and accountability in the company’s operations.